Get the Stockscreener App
3.54
0.00%
0.00
After Hours:
3.55
0.010
+0.28%
Cellectar Biosciences Inc stock is traded at $3.54, with a volume of 37,222.
It is up +0.00% in the last 24 hours and up +38.28% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$3.54
Open:
$3.51
24h Volume:
37,222
Relative Volume:
0.24
Market Cap:
$15.01M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-1.0892
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
+1.14%
1M Performance:
+38.28%
6M Performance:
-30.45%
1Y Performance:
+1,207%
1-Day Range:
$3.38
$3.695
1-Week Range:
$3.38
$3.98
52-Week Range:
$0.23
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
3.54 | 15.01M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Earnings Update: Is Cellectar Biosciences Inc a potential multi baggerJuly 2025 Snapshot & Comprehensive Market Scan Reports - baoquankhu1.vn
Weekly Trades: Is Cellectar Biosciences Inc a top pick in the sector - baoquankhu1.vn
What’s the fair value of Cellectar Biosciences Inc. stock - mfd.ru
Stock Analysis: What is the Moat Score of NAMIJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Can Cellectar Biosciences Inc disrupt its industryJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
What catalysts could drive Cellectar Biosciences Inc. stock higherMarket Insider Reports & Low Risk Trading Ideas - bollywoodhelpline.com
Fundamentals Check: How volatile is Cellectar Biosciences Inc stockWeekly Gains Report & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Ideas Watch: How cyclical is Cellectar Biosciences Incs revenue streamWeekly Stock Analysis & Accurate Intraday Trade Tips - baoquankhu1.vn
Aug Technicals: Does Cellectar Biosciences Inc have a sustainable dividendQuarterly Earnings Report & Smart Allocation Stock Reports - baoquankhu1.vn
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference - marketscreener.com
Cellectar Advances CLR 125 Into Early Breast Cancer Trial, Adding Depth to Its Radiotherapy Pipeline - TipRanks
Cellectar Biosciences to highlight strategic initiatives for 2026 - marketscreener.com
Cellectar Biosciences Outlines 2026 Strategic Plan and Regulatory Milestones for Iopofosine I 131 and CLR 125 at Biotech Showcase - Quiver Quantitative
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase ... - bdtonline.com
Cellectar Biosciences to Highlight Strategic Initiatives - GlobeNewswire
HOKA Comfort Guide: Is Cellectar Biosciences Inc. stock dividend yield sustainableWide Width Options & support options for steady strides - Улправда
How Cellectar Biosciences Inc. stock performs in rate cut cyclesWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - Улправда
Sentiment Review: What catalysts could drive Cellectar Biosciences Inc stock higherPortfolio Profit Report & Low Risk Entry Point Guides - Bộ Nội Vụ
ABTBiotech Stocks Forge Ahead With Confidence on This Week's Healthy Biotech Rally - ADVFN
Why retail investors favor Cellectar Biosciences Inc. stockStop Loss & Real-Time Buy Signal Notifications - Улправда
Momentum Shift: Will Cellectar Biosciences Inc. stock outperform value stocksMarket Performance Recap & Weekly High Conviction Trade Ideas - Улправда
Published on: 2026-01-09 06:04:32 - Улправда
Is Cellectar Biosciences Inc. stock ready for breakoutForecast Cut & High Yield Stock Recommendations - Улправда
Trend Report: What catalysts could drive Cellectar Biosciences Inc. stock higherWeekly Market Summary & Fast Entry Momentum Trade Alerts - Улправда
Bond Watch: Why retail investors favor Cellectar Biosciences Inc. stock2025 Volume Leaders & Weekly Momentum Stock Picks - Улправда
Is Cellectar Biosciences Inc. stock a buy before product launchesWeekly Loss Report & AI Forecast Swing Trade Picks - Улправда
Is Cellectar Biosciences Inc. stock attractive for retirement portfoliosJuly 2025 Sentiment & Proven Capital Preservation Methods - Улправда
Will Cellectar Biosciences Inc. stock beat EPS estimatesJuly 2025 Sector Moves & Community Verified Watchlist Alerts - Улправда
Why Cellectar Biosciences Inc. stock could rally in 2025Earnings Per Share Trends & Affordable Market Strategies - Улправда
Trade Report: Why Rezolve AI PLC stock appeals to dividend seekersWeekly Trading Summary & Fast Momentum Entry Tips - moha.gov.vn
What drives Cellectar Biosciences Inc stock priceHealthcare Stock Analysis & Affordable Growth Trading - earlytimes.in
Targets Report: Why retail investors favor Cellectar Biosciences Inc stockMarket Growth Review & Accurate Entry/Exit Alerts - moha.gov.vn
Layoff Watch: Will Cellectar Biosciences Inc stock outperform value stocksBond Market & Community Verified Trade Signals - Bộ Nội Vụ
Can Ahimsa Industries Limited Regain Momentum After BreakdownMarket Rumors and News & Affordable Stock Market Tips - earlytimes.in
Will Cellectar Biosciences Inc. stock reach Wall Street targets2025 Investor Takeaways & Real-Time Volume Spike Alerts - Улправда
How Cellectar Biosciences Inc. (NV4) stock reacts to weak economyJuly 2025 WrapUp & Smart Allocation Stock Reports - Bölüm Sonu Canavarı
Will Cellectar Biosciences Inc. stock benefit from sector rotation2025 Stock Rankings & Low Volatility Stock Suggestions - Улправда
Why Cellectar Biosciences Inc. stock remains undervaluedJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - Улправда
Aug Swings: Will Cellectar Biosciences Inc. stock reach Wall Street targets2025 Historical Comparison & Weekly Watchlist of Top Performers - ulpravda.ru
How Cellectar Biosciences Inc. stock trades before earningsJuly 2025 Volume & Low Risk Entry Point Tips - Улправда
Should I buy Cellectar Biosciences Inc. (NV4) stock before earnings seasonJuly 2025 Update & Real-Time Market Trend Scan - DonanımHaber
What MACD trends signal for Cellectar Biosciences Inc. (NV4) stock2025 Short Interest & Verified Momentum Stock Alerts - Улправда
Bond Watch: Why Cellectar Biosciences Inc. stock could rally in 2025July 2025 Setups & Momentum Based Trading Ideas - Улправда
Cellectar Biosciences announces supply agreement with Ionetix - MSN
Cellectar Biosciences, Inc. (CLRB) director John Neis reports stock sale - Stock Titan
Cellectar secures multi-year supply of alpha-emitting radioisotopes By Investing.com - Investing.com Australia
Cellectar Biosciences : Statement of Changes in Beneficial Ownership (Form 4) - marketscreener.com
Cellectar Biosciences announces strategic supply agreement with Ionetix - marketscreener.com
Cellectar Biosciences (CLRB) Secures Supply Agreement for Radioi - GuruFocus
Cellectar secures multi-year supply of alpha-emitting radioisotopes - Investing.com
Cellectar Biosciences Announces Multi-Year Supply Agreement with Ionetix for Alpha-Emitting Radioisotopes - Quiver Quantitative
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):